Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | THPO | P40225 | 1/20 | 0.45 |
| ▸ | MTOR | P42345 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6963643 | 0.87 | LMNA (0.54) | ALDH1A1NPC1GAAHTTSMN1; SMN2 | |
| SCHEMBL6966188 | 0.87 | HSD17B10 (0.48) | ALDH1A1NPC1GAANFKB1HTT | |
| SCHEMBL11319195 | 0.84 | SMN1; SMN2 (0.54) | ALDH1A1NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL11306755 | 0.83 | SMN1; SMN2 (0.55) | ALDH1A1NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL9536296 | 0.79 | HRH3 (0.46) | ALDH1A1MAPTHRH1 | |
| SCHEMBL6965021 | 0.76 | ACKR3 (0.44) | ALDH1A1NPC1GAANFKB1HTT | |
| SCHEMBL7130164 | 0.76 | SMN1; SMN2 (0.68) | ALDH1A1NPC1GAANFKB1HTT | |
| SCHEMBL6277877 | 0.75 | ALDH1A1 (0.57) | ALDH1A1NPC1GAARAB9ASMN1; SMN2 | |
| SCHEMBL6955316 | 0.74 | RAB9A (0.52) | ALDH1A1NPC1GAANFKB1HTT | |
| SCHEMBL6953393 | 0.72 | SMN1; SMN2 (0.52) | ALDH1A1NPC1GAANFKB1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6960606-B2 | Adamantyl Thiazole Thioureas | PARKER HUGHES INSTITUTE (US) | 2005-11-01 | — | — | US | disclosed |
| US-20030207921-A1 | Aromatic and heterocyclic thiazolyl thiourea compounds and use | PARKER HUGHES INSTITUTE (US) | 2003-11-06 | — | — | US | disclosed |
| EP-1326852-A1 | AROMATIC AND HETEROCYCLIC THIAZOLYL THIOUREA COMPOUNDS AND USE | Parker Hughes Institute (US) | 2003-07-16 | — | — | EP | disclosed |
| EP-0540143-B1 | Compounds and methods for inhibition of HIV and related viruses | MEDIVIR AB (SE) | 2003-02-05 | — | — | EP | disclosed |
| WO-2002032889-A1 | AROMATIC AND HETEROCYCLIC THIAZOLYL THIOUREA COMPOUNDS AND USE | PARKER HUGHES INSTITUTE (US) | 2002-04-25 | — | — | WO | disclosed |
| US-5714503-A | Compounds and methods for inhibition of HIV and related viruses | MEDIVIR AB (SE) | 1998-02-03 | — | — | US | disclosed |
| US-5658907-A | THIOUREA VIRICIDES | MEDIVIR A/B (SE) | 1997-08-19 | — | — | US | disclosed |
| US-5593993-A | VIRICIDES FOR HTLV TREATMENT OF AIDS | MEDIVIR AB (SE) | 1997-01-14 | — | — | US | disclosed |
| EP-0540143-A2 | Compounds and methods for inhibition of HIV and related viruses | Medivir Aktiebolag (SE) | 1993-05-05 | — | — | EP | disclosed |
| WO-1993003022-A1 | COMPOUNDS AND METHODS FOR INHIBITION OF HIV AND RELATED VIRUSES | MEDIVIR AB (SE) | 1993-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207921-A1 | Aromatic and heterocyclic thiazolyl thiourea compounds and use | TYMP, PNP, TPMT | ACHE 2134/4885ALDH1A1 2972/4885NPC1 985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.